Medications that lower blood pressure don’t appear to influence the progression of Parkinson’s disease, a study reports. The study, “Antihypertensive drugs may not delay the symptom progression of Parkinson’s disease: A 2-year follow-up study,” was published in Heliyon. The symptoms of Parkinson’s disease are caused…
Intensive treadmill exercise improved motor and cognitive function in a rat model of Parkinson’s disease and was linked to its ability to restore a cellular process called neuroplasticity in a recent study. Neuroplasticity refers to the brain’s ability to adapt and re-wire in response to new experiences. “We have…
IntelGenx has finalized a research grant agreement with Karolinska University Hospital, Sweden for a placebo-controlled clinical study of Montelukast VersaFilm, an experimental oral thin film formulation for Parkinson’s disease. Manufacturing of both the treatment and its placebo are underway ahead of the study, which will be led by…
From yoga therapy in Miami, Florida to a Ruston, Louisiana music and movement program, the Parkinson’s Foundation has awarded nearly $1 million in 2023 community grants for Parkinson’s disease programs that span 34 U.S. states and include international centers in Canada and Germany. The foundation’s community…
InSilicoTrials and Axoltis Pharma are teaming up to conduct computer-based studies — using both artificial intelligence (AI) and machine learning — that will test the potential therapeutic effect of Axoltis’ treatment candidate NX210c on virtual patients with Parkinson’s disease and other neurological disorders. “We are thrilled to…
Researchers have found a novel mechanism through which mutations in a gene called PRKN, linked with early-onset Parkinson’s disease, play a crucial role in familial forms of the disorder. The study found that PRKN gene mutations lead to a disruption in the communication between two vital components within the…
DGX-001, an experimental oral therapy that Viage Therapeutics is developing to treat cognitive problems associated with Parkinson’s disease, appears to work as expected in people, based on data from a Phase 1 study that tested it in healthy volunteers. Results also suggested that the therapy had a positive safety…
A digitally delivered dual-task training (DTT) program was just as good as a standard physical therapist-led one at improving gait in people with Parkinson’s disease, a small clinical trial suggests. Eight-week DTT programs, which are designed to improve patients’ ability to multitask when moving, led to significantly increased gait…
Skin cells from people with Parkinson’s disease were transformed into stem cells that could generate dopamine-producing neurons, the same type that’s progressively lost with the disease. The technique opens new avenues for cell therapies to treat Parkinson’s while avoiding possible immune rejections. The researchers used animal models of the…
Activating the Nurr1 protein eased both motor and smell deficits and showed neuroprotective properties in mouse and cell models of Parkinson’s disease in a recent study. The newly developed Nurr1 activator, called 4A7C-301, also did not induce dyskinesia, the involuntary movements associated with certain standard Parkinson’s treatments,…
Get regular updates to your inbox.
